• Economy
  • Investing
Long Distance Investing
  • Stock
  • Editor’s Pick
Investing

How to capitalize on the weight loss revolution with Tema Obesity & Cardiometabolic ETF (HRTS)

by July 27, 2024
written by July 27, 2024

Obesity is an increasingly problematic issue, especially among the richer western countries. It is caused by genetic, environmental, and dietary factors.

A staggering 42% of the US population is considered obese, a problem that the country and its people are struggling to deal with.

Problems like these create opportunities for innovative minds. One such innovation was witnessed last year when Novo Nordisk launched the first weight loss drug.

This sparked a weight loss revolution that prompted many drug companies to accelerate research on their own weight loss drug. Today, most companies have their own variant and continue to improve their research in the field.

Investors around the world consider this revolution a great money making opportunity. But picking stocks is a dangerous game, especially in the biotech sector.

Just like obesity gave rise to the weight loss drug, the risks of stock picking gave birth to the Exchange Traded Funds.

Today we look at one of those funds: the Tema Obesity & Cardiometabolic ETF (NASDAQ:HRTS)

Tema Obesity & Cardiometabolic ETF

The HRTS ETF focuses on treatments for obesity as well as cardiometabolic therapies. Despite being relatively new to the market, the ETF has fared well against its more established peers. This shows there is enough room for new ETFs in the market and a bet on a newer entry can pay dividends.

The HRTS is also unique in the sense that it doesn’t just cover obesity from the weight loss perspective. It also includes companies dealing in medical devices, insurance, supply chain, and cardiometabolic therapies.

In short, multiple different businesses that are likely to benefit from treating obesity are included in this ETF.

The ETF is further diversified by exposure to three different types of companies. There are established high growth players like Eli Lily and Novo Nordisk. Then there are stable cash-flows rich companies like Amgen.

And at last, the ETF gives exposure to high-risk biotech startups. Biotech startups are an extremely risky investment and therefore a high degree of knowledge is required to identify these companies. The fact that this ETF takes on the challenge shows the confidence and capabilities of its management.

When should you enter?

The US stock market is just taking a breather after hitting all-time highs. The HRTS ETF is doing the same as shown in the chart below.

The AI rally has over extended the market but on a deeper look, its mainly the technology stocks that have lead the way while the rest of the market has stayed relatively flat. Tech stocks are currently taking a heavy correction.

If that continues, investors may get a better entry price. However, considering the hype around weight loss drugs, the HRTS is unlikely to come down much lower. Hence, investors may want to start taking position in the ETF.

The post How to capitalize on the weight loss revolution with Tema Obesity & Cardiometabolic ETF (HRTS) appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Bitcoin, Aave, BitTorrent, Conflux forecasts ahead of Trump’s speech
next post
Blackjack in focus as Mark Cuban takes a positive tone on BTC

You may also like

MEXC strengthens reserve backing with $390M asset increase

April 23, 2025

Oil prices rebound: what’s driving the rally and...

April 23, 2025

Silver rises with gold, but industrial demand outlook...

April 23, 2025

Lead Edge Capital founder Mitchell Green says recession...

April 23, 2025

Why is Toncoin price rising today?

April 23, 2025

BC.GAME to host ‘Untamed Arena’ during TOKEN2049 Dubai,...

April 23, 2025

Keycard launches pre-sale for Shell: the most open,...

April 23, 2025

BA stock rises as Boeing reports smaller Q1...

April 23, 2025

US stocks surge at open: Dow climbs 2.4%,...

April 23, 2025

iExec launches 1M $RLC fund to support AI...

April 23, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • Krispy Kreme stock plunges after doughnut chain pauses McDonald’s rollout, pulls outlook

      May 8, 2025
    • UnitedHealthcare sued by shareholders over reaction to CEO’s killing

      May 8, 2025
    • Semtech Showcases Next-Gen LoRa® Technology at IoT Solutions World Congress 2025

      May 8, 2025
    • AMD CEO calls China a ‘large opportunity’ and warns against strict U.S. chip controls

      May 7, 2025

    Categories

    • Economy (679)
    • Editor's Pick (348)
    • Investing (4,555)
    • Stock (820)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: Longdistanceinvestings.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 Longdistanceinvestings.com

    Long Distance Investing
    • Economy
    • Investing
    Long Distance Investing
    • Stock
    • Editor’s Pick